Xerostomia (Dry Mouth) Therapeutics Market Research Report by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), End-User (Hospitals, Dental Clinics, Home Care Settings, and Others), Product Type (Salivary Stimulants, Saliva Substitutes, Dentifrices, and Others), and by Region- Global Forecast to 2034
June-2025 Formats | PDF | Category: Healthcare | Delivery: 24 to 72 Hours
“The Xerostomia (Dry Mouth) Therapeutics Market industry is expected to expand from 834.5 Million in 2025 to $ 1.28 Billion in 2034, with a compound annual growth rate of 5.6% “
Xerostomia (Dry Mouth) Therapeutics Market: Overview and Growth in the Upcoming Year
The market for treatments for xerostomia, or dry mouth, is one sector of the healthcare sector that is growing rapidly. As more people suffer from dry mouth symptoms for a variety of reasons, including medications, diseases, or lifestyle choices, there is an increasing need for effective treatments. This study will look at the current status of the Xerostomia (Dry Mouth) Therapeutics market as well as potential growth opportunities for the upcoming year.
Xerostomia, another name for dry mouth, is a condition where the mouth does not produce enough saliva. This can lead to pain, difficulty chewing and swallowing, and an increased risk of dental issues like cavities and gum disease. Xerostomia can be caused by medications such as antidepressants and antihistamines, as well as medical conditions like diabetes and Sjogren’s syndrome.
The market for Xerostomia (Dry Mouth) Therapeutics is being driven by patients’ and healthcare professionals’ growing awareness of the negative impacts of dry mouth on overall oral health and quality of life. As a result, new therapeutic strategies that effectively manage and reduce dry mouth symptoms are desperately needed. Pharmaceutical companies and research institutions are putting a lot of effort into creating new medications and treatment modalities to address this unmet medical need.
The market for Xerostomia (Dry Mouth) Therapeutics is being driven by several factors. The ageing of the population, the increase in chronic diseases, and the rising use of medications that cause dry mouth are all contributing factors to the market’s growth. Furthermore, the advancement of personalised medicine and advancements in drug delivery technology are creating new growth and innovation opportunities in the field of xerostomia therapies.
It is projected that the market for Xerostomia (Dry Mouth) Therapeutics will grow gradually over the course of the upcoming year as new product launches and clinical advancements support worldwide growth. The market is expected to grow as a result of the increased focus on individualised treatment plans and patient-centric care. However, problems like regulatory restrictions and pricing pressures may have an impact on market dynamics and prevent the growth of the industry.
For Insights Consultancy’s latest market intelligence study, “Global Xerostomia (Dry Mouth) Therapeutics Market 2025, Growth Opportunities, and Forecast,” provides a comprehensive analysis of the Food industry. The report includes demand analysis, industry insights, competition intelligence, and a customer database. It also offers strategic insights into future trends, growth determinants, supplier landscape, demand landscape, CAGR, and pricing analysis. The study also includes Porter’s Five Forces Analysis, PESTLE Analysis, Value Chain Analysis, 4 Ps’ Analysis, Market Attractiveness Analysis, BPS Analysis, and Ecosystem Analysis.
*Note: Sample of the report provides details on the scope and coverage, table of contents, research methodology, and Sample Framework of the report. Actual report of 110+ is available for purchase to all the interested stakeholders.
Xerostomia (Dry Mouth) Therapeutics Market Key Takeaways
Regional Contribution to Market in 2024:
In 2024, the Asia-Pacific region is expected to see the fastest growth in the Xerostomia (Dry Mouth) Therapeutics market. This is explained by the increasing number of elderly people, the increased awareness of dental health, and the availability of state-of-the-art treatment options in countries such as China and India.
Fastest Growing Region and Leading Region:
The market for Xerostomia (Dry Mouth) Therapeutics is anticipated to grow at the fastest rate in the Asia-Pacific area in 2024. The market for Xerostomia (Dry Mouth) Therapeutics is currently dominated by North America because of its well-established healthcare system, high adoption of innovative treatment options, and growing patient population with dry mouth diagnoses.
Market Breakdown by Type:
Salivary Stimulants, Salivary Substitutes, Prescription Medications
Fastest Growing Sub-Segment:
The subsegment of Xerostomia (Dry Mouth) Therapeutics with the fastest growth rate is expected to be salivary substitutes. These products provide temporary relief from the symptoms of dry mouth by lubricating the oral cavity and mimicking the action of saliva.
Key Applications (2024 Market Share):
- Sjögren’s Syndrome
- Cancer Therapy
- Medication Side Effects
- Radiation Therapy
Fastest Growing Application (Forecast Period 2025 to2034)
It is projected that between 2025 and 2034, the use of xerostomia medications in cancer treatment will grow at the fastest rate. Effective therapeutic solutions are more important because dry mouth is a frequent side effect of cancer treatments like chemotherapy and radiation therapy.
Report Attributes
Metric | Details |
Market Size in 2025 | USD 834.5 Million |
Projected Market Size in 2034 | USD $ 1.28 Billion |
CAGR (2025 – 2034) | 5.6% |
Market Segmentation | By Application, by End-User, and By Region |
Top Key Players | Advanz Pharma Corp. Limited, Bausch Health Companies Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin Limited, 3M company, Parnell Pharmaceuticals Inc., Pharmascience Inc (Pendopharm), Quest Products Inc. |
Customization Scope | Report customization (equivalent to up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Top Companies Covered In This Report:
The Xerostomia (Dry Mouth) Therapeutics Market’s competitive environment provides a thorough examination of the major participants. Company summaries, financial results, revenue generation, market potential, R&D expenditures, new market strategies, regional presence, strengths and weaknesses, product launches, product range, and application leadership are some of the data it contains. These statistics particularly relate to the businesses’ operations and areas of concentration in the Xerostomia (Dry Mouth) Therapeutics market.
- Advanz Pharma Corp. Limited
- Bausch Health Companies Inc.
- Fresenius SE & Co. KGaA
- GlaxoSmithKline PLC
- Hikma Pharmaceuticals PLC
- Lupin Limited
- 3M company
- Parnell Pharmaceuticals Inc.
- Pharmascience Inc (Pendopharm)
- Quest Products Inc.
Industry News
September 29, 2023 Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA®
LAVAL, Quebec, September 29, 2023 – Bausch + Lomb Corporation (“Bausch + Lomb”) (NYSE/TSX: BLCO), a subsidiary of Bausch Health Companies Inc. (the “Company” or “Bausch Health”), announced it has completed its acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5%, a non- steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2034, Y-o-Y growth rate, and CAGR):
Segment ByProduct Type
- Salivary Stimulants
- Saliva Substitutes
- Dentifrices
- and Others
Segment by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- and Others
Segment by End-User
- Hospitals
- Dental Clinics
- Home Care Settings
- and Others
Regional Deep-dive Analysis:
The report provides in-depth qualitative and quantitative data on the Xerostomia (Dry Mouth) Therapeutics Market for all of the regions and countries listed below:
North America
United States
A number of factors, such as the ageing population and the extensive use of medications, contribute to the high prevalence of dry mouth in the United States. The demand for xerostomia therapies is rising in the US as a result of the wide range of treatments available to address patient needs.
Canada
In a similar vein, Canada’s xerostomia treatment market is growing. Innovative treatment options are becoming more and more necessary as dry mouth becomes more prevalent among Canadians. Pharmaceutical companies in Canada are focusing on developing innovative therapies to address the needs of individuals with xerostomia.
Asia-Pacific
China
One of the largest markets for Xerostomia (Dry Mouth) Therapeutics in the Asia-Pacific area, China, is seeing an increase in demand for these products. This is explained by the increase in cases of dry mouth caused by factors such as tobacco use, medication use, and population ageing. Because of the government’s focus on improving the nation’s healthcare system and increasing awareness of dental health issues, the Chinese market is growing.
Japan
Due to the country’s ageing population and high prevalence of conditions like Sjogren’s syndrome, which frequently causes dry mouth, the market for Xerostomia (Dry Mouth) Therapeutics is also growing in Japan. The country’s advanced healthcare system and strong emphasis on oral care product research and development are driving the market even more.
India
India is emerging as one of the Asia-Pacific region’s main markets for Xerostomia (Dry Mouth) Therapeutics for a variety of reasons, such as changing lifestyle habits, rising awareness of oral health, and increased disposable income. The growth of dental clinics and the availability of a wide range of dry mouth treatment options are also propelling the market’s expansion in India.
Europe
Germany
The primary drivers of the Xerostomia (Dry Mouth) Therapeutics market in Germany are the existence of significant competitors, advanced healthcare infrastructure, and an ageing population. The country’s stringent requirements for approving medications ensure the efficacy and safety of xerostomia treatment options.
France
Another major rival in the European market for Xerostomia (Dry Mouth) Therapeutics is France, which places a strong focus on healthcare research and development. Modern dry mouth treatment products are widely used in the country, which encourages the market’s overall growth.
United Kingdom
As people in the UK become more aware of the significance of maintaining good oral hygiene and overall health, the demand for Xerostomia (Dry Mouth) Therapeutics is increasing. Many dry mouth remedies are readily available thanks to the country’s well-established healthcare system.
Middle East and Africa
Saudi Arabia
Saudi Arabia in particular has become a vital market for Xerostomia (Dry Mouth) Therapeutics as more pharmaceutical companies invest in R&D to bring innovative and creative solutions to meet the needs of patients with dry mouth. The market is also growing as a result of government initiatives to improve the healthcare system in the area and increase public awareness of oral health.
UAE
In the United Arab Emirates (UAE), the need for Xerostomia (Dry Mouth) Therapeutics is also being fueled by an increase in the elderly population and the prevalence of chronic illnesses that can cause dry mouth. With a focus on providing easily accessible and affordable healthcare services, the UAE government is working to ensure that individuals with xerostomia have access to high-quality treatment options to improve their quality of life.
South Africa
Because of South Africa’s advanced healthcare system and growing pharmaceutical industry, there are more Xerostomia (Dry Mouth) Therapeutics available to treat dry mouth. Because of the government’s focus on promoting preventative care and increasing awareness of oral health issues, the country’s market is growing.
The research provides answers to the following key questions:
- What is the expected growth rate of the Xerostomia (Dry Mouth) Therapeutics Market from 2025-2034?
- What are the key driving forces shaping the market during the forecast period?
- Who are the major market vendors and what winning strategies have helped them occupy a strong foothold in the Xerostomia (Dry Mouth) Therapeutics Market?
- What are the prominent market trends influencing the market’s development?
Key insights provided by the report that could help you take critical strategic decisions?
- Regional reports analyse product/service consumption and market factors in each region.
- Reports highlight possibilities and dangers for suppliers in the Xerostomia (Dry Mouth) Therapeutics Market business globally.
- The report identifies regions and sectors with the highest growth potential.
- It provides a competitive market ranking of major companies, as well as information on new product launches, partnerships, business expansions, and acquisitions.
- The report includes a comprehensive corporate profile with company overviews, insights, product benchmarks, and SWOT analysis for key market participants.
Customization: We can provide following things
1) On request more company profiles (competitors)
2) Data about particular country or region
3) We will incorporate the same with no additional cost (Post conducting feasibility).
Any Requirement Contact us: https://www.forinsightsconsultancy.com/contact-us/
Table of Contents
For TOC Contact us: https://www.forinsightsconsultancy.com/contact-us/
